Condition: Advanced Pancreatic Cancer · Sponsor: Abbisko Therapeutics Co, Ltd
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Complete the study procedures specified in the protocol, which is guided by researchers.
This description comes directly from the study's public registry record.
YUAN LU · +86-21-68910052 · clinical@abbisko.cn
Always discuss trial participation with your own doctor first.
| Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| Harbin Medical University Cancer Hospital | Ha’erbin, China | Recruiting |
| Shanghai East Hospital Tongji University | Shanghai, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of science and technolog | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06111274